Table 5.

Selected Smaller Cancer Prevention Trials and Studies

Study Name NCT Identifier	Sponsoring Organization	Intervention	Study Size	Time of Accrual	Results
E5597 Lung cancer	Eastern Cooperative Oncology Group http://www.ecog.org/	Selenium vs. placebo to prevent second lung cancers in people with early stage non-small cell lung cancer	1,960 lung cancer patients	October 2000 to November 2009	Selenium supplementation was safe, but conferred no benefit over placebo in the prevention of second primary tumors in patients with resected non-small cell lung cancers.
RTOG-9115 Head and neck cancer	Radiation Therapy Oncology Group, now part of NRG Oncology http://www.rtog.org/	Low-dose isotretinoin to prevent second cancers in stage I and II head and neck cancer patients	1,190 head and neck cancer patients	November 1991 to June 1999	Isotretinoin did not reduce the number of second primary tumors in this population. Smoking increased the risk of second primary cancers and death.
MDA-ID-91025 Lung	University of Texas M.D. Anderson Cancer Center http://www.mdanderson.org/	Istretinoin to prevent second primary lung cancers in people with stage I non-small cell lung cancer	1,166 lung cancer patients	December 1992 to April 1997	No difference was seen between placebo and intervention in second primary cancers, recurrence, or mortality.
Colorectal Adenoma Prevention Study (CAPS) CALGB	Cancer and Leukemia Group B (CALGB), now part of the Alliance for Oncology http://www.allianceforclincicaltrialsinoncology.org	Aspirin vs. placebo in people with surgically-cured early stage colorectal cancer	635 colorectal cancer patients	May 1993 to January 2000	Daily aspirin use reduced the development of adenomas by 35%. Aspirin treatment also reduced the number of adenomas and increased the time before adenomas developed, without significant adverse events.
Selenium in Preventing Cancer in Patients with Neoplasia of the Prostate S9917 NCT00030901	Southwest Oncology Group http://swog.org	Selenium vs. placebo to prevent prostate cancer in men with high-grade Prostatic Intraepithelial Neoplasia	452 men with high-grade PIN	February 2000 to November 2006	Selenium supplementation had no effect on prostate cancer risk.
National Ovarian Cancer Prevention and Early Detection Study GOG-0199 NCT01139957	Gynecology Oncology Group, now part of NRG Oncology http://www.gog.org/	Prospective study of risk-reducing salpingooopherectomy and longitudinal CA-125 screening assay among women at increased genetic risk	1,916 women at increased risk of ovarian cancer, especially BRCA1/2 carriers	June 2003 to November 2006	Initial results show 2.6% of women who underwent surgery had ovarian cancer, despite no clinical signs of disease.